Clinical and preclinical photodynamic therapy

Lasers in Surgery and Medicine

Volumn 17, Issue 1, 1995, Pages 2-31

  Fisher, Anita M R ^a,b   Murphree, A Linn ^a,b   Gomer, Charles J ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

lasers; oxidative stress; photodynamic therapy; Photofrin; photomedicine; photosensitizers; tumor

Indexed keywords

PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; PORPHYRIN; PURPURIN;

ATHEROSCLEROSIS; BLADDER CANCER; BLOOD VESSEL INJURY; BRAIN TUMOR; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; DOSIMETRY; EYE CANCER; HYPERTHERMIA; KAPOSI SARCOMA; LASER; LIPOPROTEIN BLOOD LEVEL; LUNG CANCER; OXIDATIVE STRESS; PHOTOCHEMISTRY; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; TUMOR CELL DESTRUCTION; VIRUS INFECTION;

ANIMAL; CLINICAL TRIALS; HEMATOPORPHYRIN DERIVATIVE; HUMAN; LASERS; NEOPLASMS; PHOTOBIOLOGY; PHOTOCHEMISTRY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; VIRUS DISEASES;

EID: 0029080737     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.1900170103     Document Type: Review

References (242)

1. Uber die wirkung fluoreszierenden stoffen
2. The sensitising action of hematoporphyrin
3. Cancer detection and therapy. Affinity of neoplastic, embryonic and traumatized tissues for porphyrins and metalloporphyrins
4. Historical Perspective
5. The photodynamic properties of a particular hematoporphyrin derivative
6. Hematoporphyrin derivative: A new aid for endoscopic detection of malignant disease
7. Hematoporphyrin derivative fluorescence in malignant neoplasms
8. Photodynamic therapy of malignant tumors
9. Photoradiation therapy II: Cure of animal tumors with hematoporphyrin and light
10. Photodynamic destruction of human bladder carcinoma
11. Photoradiation therapy for the treatment of malignant tumors
12. Photodynamic therapy (PRT) of malignant tumors
13. Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer
14. Photodynamic therapy of early stage lung cancer
15. Photodynamic therapy of esophageal carcinoma
16. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional cell carcinoma of the bladder
17. The structure of the active component of hematoporphyrin derivative
18. Chlorins as photosensitizers in biology and medicine
19. Chlorin and porphyrin derivatives as potential photosensitizers in photodynamic therapy
20. Reduced porphyrins as photosensitizers: synthesis and biological effects
21. In vitro evaluation of phototoxic properties of four structurally related benzoporphyrin derivatives
22. Phthalocyanines as photodynamic sensitizers
23. The chemistry, photophysics and photosensitizing properties of phthalocyanines
24. Phthalocyanines as sensitizers for PDT of cancer
25. Determination of 3H and 14C hematoporphyrin derivative distribution in malig nant C and normal tissue
26. Distribution and elimination of Photofrin II in mice
27. A comparison of serum kinetics and tissue distribution of photofrin II following intravenous and intraperitoneal injection in the mouse
28. Tumor scanning with indium–111 dihaematoporphyrin ether
29. Therapeutic ratio of photodynamic therapy in the treatment of superficial tumors of skin and subcutaneous tissues in man
30. The quantitative determination of porphyrins in tissues and body fluids: Applications in studies of photodynamic therapy
31. Pharmacokinetics of Photofrin II distribution in man
32. Tissue distribution and photosensitizing properties of mono‐L‐aspartyl chlorin e6 in a mouse tumor model
33. Photosensitizing efficiency of two regioisomers of the benzoporphyrin derivative monoacid ring A
34. In vivo transport and pharmacokinetic behavior of tumor photosensitizers
35. Strategies for selective cancer photochemotherapy: Antibody targeted and selective carcinoma cell photolysis
36. Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems
37. Development of technology for linking photosensitizers to a model monoclonal antibody
38. Approaches to targetted photodynamic tumor therapy
39. The role of lipoproteins in the delivery of tumour‐targeting photosensitizers
40. Cellular uptake and photosensitizing properties of anticancer porphyrins in cell membranes and low and high density lipoproteins
41. Low density lipoproteins—Liposome delivery systems for tumor photosensitizers in vivo
42. The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution
43. The effects of plasma lipoproteins on invitro tumor cell killing and invivo tumor photosensitization with benzoporphyrin derivative
44. Tumour localizing properties of porphyrins: In vivo studies using free and liposome encapsulated aminolevulinic acid
45. Photoimmunotherapy: Treatment of animal tumors with tumor‐specific monoclonal antibodies‐hematoporphyrin conjugates
46. Antibody‐targeted photolysis
47. Biodistribution of a benzoporphyrin derivative‐monoclonal antibody conjugate in A549‐tumor‐bearing nude mice
48. Photodynamic therapy in gynecological oncology
49. Penetration of tumor tissue by antibodies and other immunoproteins
50. Mechanisms of photooxidation
51. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor
52. Hydrogen peroxide and hydroxyl free radical production by hematoporphyrin derivative, ascorbate and light
53. Properties and applications of photodynamic therapy
54. Photosensitization with derivatives of hematoporphyrin
55. Sites of photosensitization by derivatives of hematoporphyrin
56. Hematoporphyrin derivative induced photosensitivity of mitochondrial succinate dehydrogenase and selected cytosolic enzymes of R3230 AC mammary adenocarcinomas of rats
57. Photosensitization of Wi26‐VA4 transformed human fibroblasts by low density lipoprotein loaded with Photofrin II: Evidence for endoplasmic reticulum alteration
58. Depolarization of mouse myeloma cell membranes during photodynamic action
59. Photodynamic effects of hematoporphyrin derivative on transmembrane transport systems of murine L929 fibroblasts
60. Chlorins as photosensitizers in biology and medicine
61. DNA damage and repair in CHO cells following hematoporphyrin photoradiation
62. DNA singlestrand breaks and sister chromatid exchanges induced by treatment with hematoporphyrin and light or by X‐rays in human NHIK 3025 cells
63. Differential cell photosensitivity following porphyrin photodynamic therapy
64. DNA lesions and DNA degradation in mouse lymphoma L5178Y cells after photodynamic treatment sensitized by chloroaluminium phthalocyanine
65. Cytotoxic and mutagenic effects of the photodynamic action of chloroaluminium phthalocyanine and visible light in L5178Y cells
66. Transformation and mutagenic potential of porphyrin photodynamic therapy in mammalian cells
67. Glucose regulated protein induction and cellular resistance to oxidative stress mediated by porphyrin photosensitization
68. Increased transcription and translation of heme oxygenase in chinese hamster fibroblasts following photodynamic stress or Photofrin II incubation
69. Adriamycin resistance in Chinese hamster fibroblasts following oxidative stress induced by photodynamic therapy
70. Signal transduction in PDT‐induced apoptosis
71. Apoptosis during photodynamic therapy induced ablation of RIF‐1 tumors in C3H mice
72. Changes in perfusion of mouse tumours after photodynamic therapy
73. Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin and phthalocyanine
74. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy
75. Tissue localization of photosensitizers and the mechanism of photodynamic tissue destruction
76. Release of prostaglandin E2 from cells by photodynamic treatment
77. Schuschke. The microvascular effects of photodynamic therapy: Evidence for a possible role of cyclooxygenase products
78. Role of thromboxane and prostacycline release on photodynamic therapy induced tumor destruction
79. A comparison of the effects of photodynamic therapy on normal and tumor blood vessels in the rat microcirculation
80. How does photodynamic therapy work
81. Photochemotherapy of cancer: Experimental research
82. Intramitochondrial dyes allow selective in vitro photolysis of carcinoma cells
83. Effect of tumor location on selective uptake and retention of phthalocyanines
84. Transport of molecules in the tumor interstitium: A review
85. Porphyrinlipoprotein association as a factor in porphyrin localization
86. Photoradiation therapy of brain tumors: Laboratory and clinical studies
87. Time and sequence dependent influence of in vivo photodynamic therapy survival by hyperthermia
88. Potentiation of photodynamic therapy by heat: Effect of sequence and time interval between treatments in vivo
89. Perspectives for the combined use of photodynamic therapy and hyperthermia in cancer patients
90. Porphyrin photosensitivity in cell lines expressing a heatresistant phenotype
91. Vascular function and tissue injury in murine skin following hyperthermia and photodynamic therapy, alone and in combination
92. Some preparations and properties of porphyrins
93. In vivo and postmortem measurements of the attenuation spectra of light in mammalian tissues
94. Comparison of the efficacy of pulsed and continuous wave red laser light in induction of photocytotoxicity by hematoporphyrin derivative
95. A comparison of gold vapour and dye lasers for photodynamic therapy
96. Comparison of pulsed and continuous wave light in photodynamic therapy of papillomas: An experimental study
97. Comparison of lasers for photodynamic therapy with a phthalocyanine photosensitizer
98. Hematoporphyrin derivative and pulse laser photoradiation
99. Direct comparison of invitro and invivo Photofrin‐II mediated photosensitization using a pulsed KTP pumped dye laser and a continuous wave argon ion pumped dye laser
100. Light delivery and optical dosimetry in photodynamic therapy of solid tumors
101. Laser systems for photodynamic therapy
102. The theory of photodynamic therapy dosimetry: consequences of photode‐struction of sensitizer
103. Instrumentation for Photodynamic Therapy
104. Photophysics of and instrumentation for porphyrin detection and activation
105. Photodynamic Therapy: Light Delivery And Dosage For Second‐Generation Photosensitizers
106. Transcutaneous determination of tissue dihematoporphyrin ether content: A device to optimize photodynamic therapy
107. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy
108. Current perspectives of singlet oxygen detection in biological environments
109. Detection of haematoporphyrin derivative and haemotoporphyrin excited states in cell environments
110. Experimental tests of the feasibility of singlet oxygen luminescence monitoring in vivo during photodynamic therapy
111. Global status of clinical photodynamic therapy: the registration process for a new therapy
112. An evaluation of the effectiveness of Photodynamic Therapy (PDT) compared to surgical resection in early stage roentgenographically occult lung cancer
113. A prospective phase II study on photodynamic therapy with Photofrin II for centrally located earlystage lung cancer
114. Five year disease‐free survival of lung cancer patients treated only by photodynamic therapy
115. Detection and Phototherapy of Lung Cancer
116. Photodynamic Therapy of Human Cancer
117. Photodynamic therapy of endobronchial malignancies
118. Photodynamic therapy of early stage lung cancer
119. Hematoporphyrin derivative photodynamic therapy in roentgenographically occult carcinoma of the tracheobronchial tree
120. Photodynamic Therapy (PDT) in roentgenographically occult lung cancer by Photofrin II and excimer dye laser
121. A pilot study of Photodynamic Therapy in Patients with inoperable Non‐Small Cell Lung cancer
122. Photodynamic therapy for multiple primary bronchogenic carcinoma
123. Bronchial arterial infusion of Photofrin for PDT
124. Photodynamic therapy and thermal treatment of esophageal cancer
125. Laser and photodynamic therapy of esophageal cancer
126. Barrett's esophagus: characteristics and evaluation of risk of malignancy
127. Photo‐dynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus
128. Centering balloon to improve esophageal photodynamic therapy
129. Laser endoscopic treatment for upper gastrointestinal cancers
130. Photodynamic Therapy of esophageal carcinoma
131. Photodynamic therapy of skin and esophageal cancers
132. Review of Photodynamic Therapy for gastrointestinal tumours in the past 6 years in China
133. Photodynamic therapy in oncology: Mechanisms and clinical use
134. Experiences with Photodynamic Therapy in early gastric cancer
135. Laser therapy of colorectal carcinoma
136. Photodynamic Therapy for colorectal disease
137. Phototherapy of bladder cancer
138. Carcinoma in situ
139. Fluorescence detection and photodynamic treatment of photosensitized tumors in special consideration of urology
140. Treatment system for whole bladder wall photodynamic therapy with in vivo monitoring and control of light dose rate and dose
141. In situ light dosimetry during whole bladder wall photodynamic therapy: clinical results and experimental verification
142. Whole bladder photodynamic therapy: critical review of present‐day technology and rationale for development of intravesical laser catheter and monitoring system
143. Photodynamic therapy
144. Clinical experience with the integral photodynamic therapy of bladder carcinoma
145. Improved argon laser photodynamic therapy for superficial bladder tumor: Experimental research and clinical analysis
146. Effect of 514nm Argon ion laser radiation on hematoporphyrin derivative treated bladder tumor cells in vivo and vitro
147. Photodynamic therapy of brain tumors
148. Current status of lasers in neurosurgical oncology
149. Photodynamic therapy of brain tumors
150. Photodynamic therapy of malignant glioma. A review of literature
151. Photodynamic therapy of malignant brain tumors: clinical effects, postoperative ICP and light penetration of the brain
152. Photodynamic therapy of malignant brain tumors
153. Photodynamic therapy of malignant brain tumors
154. Photodynamic therapy of malignant brain tumors: clinical results of, difficulties with, questions about, and future prospects for the neurosurgical applications
155. Photoradiation therapy and its potential in the management of neurological tumors: A review
156. Comparative study of different laser systems
157. Photodynamic therapy in gynecologic malignancies
158. Photodynamic therapy in the management of head and neck cancer
159. Photodynamic therapy of tumours involving the skin and the head and neck
160. Photodynamic therapy and the treatment of neoplastic diseases of the head and neck; an update
161. Photodynamic therapy as an adjuvant intra‐operative treatment of recurrent head and neck carcinomas
162. Photodynamic therapy for treatment of head and neck cancer
163. Photodynamic laser therapy in the field of otorhinolaryngology
164. Photodynamic therapy in head and neck surgery
165. Photodynamic therapy in the treatment of squamous cell carcinoma of the head and neck
166. Current options in the management of choroidal melanoma
167. Management of intraocular melanoma
168. Retinoblastoma
169. Lasers in uveal melanoma
170. Photodynamic therapy of ocular tumors
171. The evolution of photodynamic therapy in the treatment of intraocular tumors
172. Photodynamic therapy in dermatology: recent developments
173. Photodynamic therapy for cutaneous and subcutaneous malignant neoplasms
174. Photodynamic therapy for the treatment of basal cell carcinoma
175. Photodynamic therapy in the treatment of Bowen's disease
176. Interstitial photodynamic therapy: Clinical experience with diffusing fibres in the treatment of cutaneous and subcutaneous tumours
177. An evaluation of photodynamic therapy in the management of cutaneous metastases of breast cancer
178. Photodynamic therapy for treatment of AIDS‐related mueocutaneous Kaposi's sarcoma
179. Photodynamic therapy versus Nd: YAG laser treatment of endobronchial or esophageal malignancies
180. Thermal lasers and PDT in urology
181. Innovative photodynamic therapy at the National Cancer Institute: Intraoperative, intracavitary treatment
182. Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors
183. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms
184. Intra‐abdominal photodynamic therapy: from theory to feasibility
185. Intrathoracic organ injury associated with photodynamic therapy
186. Photodynamic therapy and bone marrow transplantation
187. Comparison of the cytotoxic effects of merocyanine 540 on leukemic cells and normal human bone marrow
188. Merocyanine 540 sensitized photoinactivation of high grade non‐Hodgkin's lymphoma cells: potential application in autologous BMT
189. Marrow purging by merocyanine 540 mediated photolysis
190. The immunoregulatory effects of merocyanine 540 on in vitro human T and B lymphocyte functions
191. Photosensitizing potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model
192. Preferential uptake of benzoporphyrin derivative by leukemic versus normal cells
193. Biodistribution of tritiated benzoporphyrin derivative (3H‐BPD‐MA), a new potent photosensitizer, in normal and tumor‐bearing mice
194. Non‐oncologic potentials for photodynamic therapy
195. Photoinactivation of HIV by benzoporphyrin derivative
196. Tissue distribution and photosensitizing properties of mono‐L‐aspartyl chlorin e6 in a mouse tumor model
197. Photodynamic therapy of superficial malignancies with NPe6 in man
198. Comparison of hematoporphyrin derivatives and new photosensitizers
199. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: Initial clinical results
200. Clinical evaluation of photodynamic therapy with mTHPC for chest malignancies
201. New photosensitizers for photodynamic therapy: Combined effect of metallopurpurin derivatives and light on transplantable bladder tumors
202. Metallopurpurins and light: Effect on transplantable rat bladder tumors and murine skin
203. New sensitizers for PDT
204. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience
205. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy
206. Oral versus intravenous administration of 5‐aminolaevulinic acid for photodynamic therapy
207. Penetration potency of topical applied delta‐aminolevulinic acid for photodynamic therapy of basal cell carcinoma
208. Superficial photodynamic therapy with topical 5‐aminolaevulinic acid for superficial primary and secondary skin cancer
209. Photochemotherapy of multiple basal cell carcinoma with endogenous porphyrins induced by topical application of 5‐amino levulinic acid
210. Photodynamic therapy of human skin malignancies and laser induced fluorescence diagnostics utilizing Photofrin and delta‐amino levulinic acid
211. Topical photodynamic therapy with endogenous porphyrins after application of 5‐aminolevulinic acid: An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas and basal cell carcinomas
212. PDT with topical amino‐levulinic acid (ALA) for the treatment of patch and plaque stage cutaneous T cell lymphoma
213. Photosensitization
214. Photodynamic inactivation of animal viruses: A review
215. Photodynamic inactivation of Herpes simplex
216. The clinical treatment of laryngeal papillomas with hematoporphyrin therapy
217. Clinical effects of photodynamic therapy on recurrent laryngeal papillomas
218. Antiviral effects of photosensitizing merocyanine dyes: Implications for transfusion and bone marrow transplantation
219. Inactivation of viruses with photoactive compounds
220. Merocyanine sensitized photoinactivation of enveloped viruses
221. Photosensitizers as virucidal agents
222. Action spectra of the antileukemic and antiviral activities of merocyanine 540
223. Merocyanine 540 sensitized photoinactivation of enveloped viruses in blood products: Site and mechanism of phototoxicity
224. Photoinactivation of HIV by benzoporphyrin derivative
225. Photodynamic therapy of atherosclerotic vascular disease
226. In vitro and in vivo uptake of benzoporphyrin derivative into atherosclerotic plaque
227. In vivo photosensitizer enhanced laser angioplasty in atherosclerotic miniswine
228. Local application of photosensitive dyes in arterial vessels
229. Treatment of arterial intimal hyperplasia with photodynamic therapy
230. Photodynamic therapy of arteries: A novel approach for the treatment of experimental intimal hyperplasia
231. Differential effect of Photofrin II on growth of human smooth muscle cells from nonatherosclerotic arteries and atheromatous plaques in vitro
232. Photomedicine
233. Photodynamic properties of Sn protoporphyrin: Clinical investigations and phototesting in human subjects
234. Psoriasis vulgaris treated with hematoporphyrin
235. Response of psoriasis to red laser light (630 nm) following systemic injection of hematoporphyrin derivative
236. Photodynamic therapy of psoriasis palmaris et plantaris using a topically applied hematoporphyrin derivative and visible light
237. Treatment of psoriasis by topical photodynamic therapy with polychromatic light
238. Lasers in cutaneous disease
239. Photochemotherapy of hypervascular dermal lesions: A possible alternative to photothermal therapy
240. Advances in laser skin surgery for vascular lesions